S.C.P.C - Interim / Quarterly Report 2022

==> picture [445 x 235] intentionally omitted <==

Standard Chem & Pharm Co., Ltd. Stock Symbol : 1720 2022 Investor Conference 11/17/2022

==> picture [280 x 75] intentionally omitted <==

免責聲明 Safe Harbor Notice

==> picture [88 x 81] intentionally omitted <==

本次簡報與討論包含特定預測性的說明，而其內容有關於營運結果、財務狀況，以及對未來事件的預期。因為此等前瞻性說明是有關於未來事件，而且取決於未來發生時的環境因素，所以必然含有風險與不確定性。

本公司將不負擔公開更新或修改這些預測性的說明之義務，無論是出現新資訊、未來發生任何
事件，或其他情況。實際結果可能與此等預測性說明推測的內容有重大差異。

In these presentations and discussions, there are certain forward looking statements regarding the results of operation, financial condition and current expectation about future events. As forward-looking statements relate to events and depend on circumstances in the future, they involve risk and uncertainty.

We do not undertake any obligation to publicly revise or update any forward looking statements for availability of new information, future events or otherwise. Real result probably differ substantially from those expected in these forward-looking statements.

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

1
----- End of picture text -----

==> picture [229 x 475] intentionally omitted <==

----- Start of picture text -----

© 2022 SCP, Ltd
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

Agenda

 Introduction of Standard Group

 2022 Q1-Q3 Operating Results

 Future Operation Strategy  Corporate Social Responsibility (CSR)

==> picture [229 x 475] intentionally omitted <==

----- Start of picture text -----

© 2022 SCP, Ltd
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

Agenda

Introduction of Standard Group

 2022 Q1-Q3 Operating Results  Future Operation Strategy  Corporate Social Responsibility (CSR)

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

3
----- End of picture text -----

==> picture [815 x 474] intentionally omitted <==

----- Start of picture text -----

SCP and Related/Affiliated Companies
Upstream Manufacture Downstream
Syn-Tech (1982; 2005 SCP(1967;
Taiwan Biosim(2017)
Over-The-Counter (OTC)) 1995 listed stock)
Western
medicine
Your Chance
Syngen(1999; 2016 OTC) Souriree(1997) (Invested in 2013;
2022 Pioneer Stock Board (PSB))
Multipower
Syngen(1999)
Healthcare (Invested in 2012)
nutrition
Sun-you(1994) Advpharma (1999)
Medical-
Syngen (1999)
devices
Q
Ho Yao Biopharm
Gene chip Advpharma (1999) (2021)
Inforight(2000)
Software/Hardware 4
service support
© 2022 SCP, Ltd
----- End of picture text -----

International Accreditation

==> picture [606 x 32] intentionally omitted <==

----- Start of picture text -----

1998 2000 2008 2009 2010 2017 2021
----- End of picture text -----

==> picture [42 x 45] intentionally omitted <==

==> picture [29 x 38] intentionally omitted <==

The first TW pharmaceutical company to be ISO9001 certified

==> picture [50 x 32] intentionally omitted <==

==> picture [46 x 25] intentionally omitted <==

The first TW company to pass US FDA inspection in 2000

Subsequent US FDA GMP inspections : no 483 Last Inspection : 2022/10/31

==> picture [28 x 37] intentionally omitted <==

SCP received JP PMDA’s FDF Plant and API Plant passed “Certificate of Foreign Drug PMDA GMP Audit in 2018 Manufacturer” in 2008

==> picture [50 x 31] intentionally omitted <==

==> picture [58 x 37] intentionally omitted <==

2009

==> picture [48 x 33] intentionally omitted <==

SCP’s API plant passed AU TGA inspection

==> picture [44 x 34] intentionally omitted <==

==> picture [48 x 36] intentionally omitted <==

2010 SCP passed TW PIC/S GMP inspection 2012 SCP is certified GDP by the T-FDA

==> picture [49 x 33] intentionally omitted <==

==> picture [70 x 31] intentionally omitted <==

2012 SCP passed K-FDA inspection

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [229 x 475] intentionally omitted <==

----- Start of picture text -----

© 2022 SCP, Ltd
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

Agenda

 Introduction of Standard Group

 2022 Q1-Q3 Operating Results  Future Operation Strategy  Corporate Social Responsibility (CSR)

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

6
----- End of picture text -----

55 Years of Continuous Profitability

0.30 0.30 0.70 1.20 1.50 1.25 1.20 1.60 0.50 1.00 1.20 2.50 1.00 1.50 1.50 1.60 1.50 1.50 1.80 2.50 2.092.15 1.771.81 1.88 1.351.47 1.61 1.73 2.09 1.95 1.90 2.03 2.09 2.11 2.93 3.95 3.58

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [595 x 44] intentionally omitted <==

		Consolidated Income Statement	Consolidated Income Statement	Consolidated Income Statement

	Items (Unless otherwise specified, expressed in thousands of New Taiwan Dollars)		2022 Q1-Q3	2021 Q1-Q3	Diff.	Annual changes (%)
		Operatingrevenue	4,268,103	3,371,013	897,090	26.6%
		Grossprofit	1,805,887	1,526,457	279,430	18.3%
		Grossprofit margin	42.31%	45.28%		-2.97pct
		Operatingexpenses	991,207	892,428	98,779	11.1%
		Operating profit	814,680	634,029	180,651	28.5%
		Non-operating income and expenses	317,843	113,148	204,695	180.9%
		Profit before income tax	1,132,523	747,177	385,346	51.6%
		Profit for theyear	927,154	625,114	302,040	48.3%
		Profit attributable to Shareholders of the parent	640,506	533,781	106,725	20.0%	Q
		EPS(NTD)	3.58	2.99	0.59	19.7%
Note 1: SYN-TECH CHEM. & PHARM. Co., Ltd. is			consolidated into the financial report since		2021.12.08.
Note 2: Consolidated profit margin decreased in			8 comparison with last year due to the consolidation of SYN-TECH's profit margin of 35.60%.
©	2022 SCP, Ltd

Comparison of Quarterly Revenue of Past 5 Years (Consolidated)

0 500,000 1,000,000 1,500,000 2,000,000 Q1 Q2 Q3 Q4 2018 2019 2020 2021 2022 18 19 20 21 22 18 19 20 21 22 18 19 20 21 18 19 20 21 22 Expressed in thousands of NTD	0 500,000 1,000,000 1,500,000 2,000,000 Q1 Q2 Q3 Q4 2018 2019 2020 2021 2022 18 19 20 21 22 18 19 20 21 22 18 19 20 21 18 19 20 21 22 Expressed in thousands of NTD	0 500,000 1,000,000 1,500,000 2,000,000 Q1 Q2 Q3 Q4 2018 2019 2020 2021 2022 18 19 20 21 22 18 19 20 21 22 18 19 20 21 18 19 20 21 22 Expressed in thousands of NTD	0 500,000 1,000,000 1,500,000 2,000,000 Q1 Q2 Q3 Q4 2018 2019 2020 2021 2022 18 19 20 21 22 18 19 20 21 22 18 19 20 21 18 19 20 21 22 Expressed in thousands of NTD	0 500,000 1,000,000 1,500,000 2,000,000 Q1 Q2 Q3 Q4 2018 2019 2020 2021 2022 18 19 20 21 22 18 19 20 21 22 18 19 20 21 18 19 20 21 22 Expressed in thousands of NTD	0 500,000 1,000,000 1,500,000 2,000,000 Q1 Q2 Q3 Q4 2018 2019 2020 2021 2022 18 19 20 21 22 18 19 20 21 22 18 19 20 21 18 19 20 21 22 Expressed in thousands of NTD	0 500,000 1,000,000 1,500,000 2,000,000 Q1 Q2 Q3 Q4 2018 2019 2020 2021 2022 18 19 20 21 22 18 19 20 21 22 18 19 20 21 18 19 20 21 22 Expressed in thousands of NTD
	Q1	Q2	Q3	Q4	Total	Growth(%)
2018	763,261	897,693	913,353	998,786	3,573,093	-7.2%
2019	846,177	1,010,837	1,048,886	1,031,229	3,937,129	+10.2%
2020	1,034,417	1,108,059	1,045,351	1,117,573	4,305,400	+9.4%
2021	1,101,113	1,149,060	1,120,840	1,233,069	4,604,082	+6.9%
2022	1,237,170	1,481,061	1,549,872		4,268,103	+26.6%
2 SCP, Ltd Note: SYN-TECH CHEM. & PHARM. Co., Ltd. is consolidated into the financial report since 2021.12.08

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

Consolidated Balance Sheet

Items	2022/9/30	2022/9/30	2021/9/30	2021/9/30	Diff.	Annual changes(%)
(Expressed in thousands of NTD)	Amount	%	Amount	%
Cash and cash equivalents	2,454,867	22.0%	1,325,452	17.9%	1,129,415	85.2%
Accounts receivable	1,424,976	12.8%	1,073,774	14.5%	351,202	32.7%
Inventories	1,322,473	11.8%	968,244	13.1%	354,229	36.6%
Investments	999,506	8.9%	1,173,217	15.8%	(173,711)	(14.8%)
Property,plant and equipment	3,529,686	31.6%	2,074,708	28.0%	1,454,978	70.1%
Others	1,436,662	12.9%	795,380	10.7%	641,282	80.6%
Total Assets	11,168,170	100.0%	7,410,775	100.0%	3,757,395	50.7%
Current Liabilities	3,306,926	29.6%	1,740,975	23.5%	1,565,951	89.9%
Non-current Liabilities	700,316	6.3%	526,817	7.1%	173,499	32.9%
Total liabilities	4,007,242	35.9%	2,267,792	30.6%	1,739,450	76.7%
Total shareholder’s equity	7,160,928	64.1%	5,142,983	69.4%	2,017,945	39.2%
Debt Ratio(Liabilities/Assets)		35.9%		30.6%
022 SCP, Ltd Note: SYN-TECH CHEM. & PHARM. Co., Ltd. is consolidated into the financial report since 2021.12.08

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

Consolidated Cash Flows

==> picture [88 x 81] intentionally omitted <==

Consolidated Cash Flows
Items	2022 Q1-Q3	2021 Q1-Q3
(Expressed in thousands of NTD)
Cash at beginning ofyear	2,564,395	1,036,183
Cash flows from operatingactivities	962,804	557,366
Acquisition ofproperty, plant and equipment	(1,010,569)	(165,908)
Cash dividends	(446,740)	(321,653)
Short-term borrowings	567,183	151,496
Investment and others	(182,206)	67,968
Cash at end ofyear	2,454,867	1,325,452

Free cash flow (Cash flows from operatingactivities-Acquisition ofproperty,plant and equipment)	(47,765)	391,458

Note: SYN-TECH CHEM. & PHARM. Co., Ltd. is consolidated into the financial report since 2021.12.08

==> picture [229 x 475] intentionally omitted <==

----- Start of picture text -----

© 2022 SCP, Ltd
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

Agenda

 Introduction of Standard Group  2022 Q1-Q3 Operating Results  Future Operation Strategy  Corporate Social Responsibility (CSR)

Future Milestone

==> picture [614 x 278] intentionally omitted <==

----- Start of picture text -----

From Taiwan to International
From Generics to Better than Generics (BTG)
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [60 x 64] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

13
----- End of picture text -----

SCP – Major International Businesses of the Past 2 Years

==> picture [88 x 81] intentionally omitted <==

==> picture [748 x 308] intentionally omitted <==

----- Start of picture text -----

Taiwan China Japan
•
• • Bronchiolitis drug, non-
Sales performance growth Continues export of antibiotic
steroid anti-inflammatory
during COVID-19 due to injection.
well-managed production • drugs are delivered
Application for Generic
and sales coordination. persistently.
Quality Consistency
•
• CDMO/CMO products in
The cumulative profit of Evaluation(GQCE) and drugs
SCP, Syn-Tech, and BE studies in process. process.
Syngen 2022 hit a new
high record in the first
three quarters of 2022.
----- End of picture text -----

==> picture [57 x 57] intentionally omitted <==

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

14
----- End of picture text -----

Revenue Growth Strate -Taiwan gy

==> picture [127 x 181] intentionally omitted <==

The EPS of 3 companies of SCP group hit record hi h in the first three uarters of 2022 g q

SCP (1720) 3.58 Syn-Tech (1777) 6.10 Syngen (8279) 9.31

Outstanding Operation

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

4 major business field
Western medicine, APIs, health food, and drugstore chain channels

Excellent operation team: SCP, Syn-Tech, Syngen, and Your Chance
July 2022, API department was split-off from SCP and transferred to Syn-Tech
October 2022, Your Chance registered for Pioneer Stock Board (6929)

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

15
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

China Market Trends: Current

China’s Drug Market continues to grow due to strengthening its medical and health system.

==> picture [57 x 57] intentionally omitted <==

Market declined in 2020 due to epidemic, but the sales growth rate picked up in 2021, and it is expected to grow in the future.

==> picture [659 x 278] intentionally omitted <==

----- Start of picture text -----

China Drug Market Scale
16,000 50.0%
14,000 40.2% 40.0%
14,063
13,782
13,313
12,000 12,931
12,436 30.0%
11,467
10,000
20.0%
8,000
8,180 12.4%
10.0%
6,000 7,277 8.5% 5.6% 6.6% 6,832
7.1%
0.0% 0.0%
4,000 Q
-8.0%
-10.0%
2,000
0 -20.0%
2014 2015 2016 2017 2018 2019 2020 2021 2022H Source： 16
Year www.menet.com.cn
Sales Growth Rate China CMH (second-level and public hospital)
Sales (CNY100Million)
----- End of picture text -----

China Market Trends: Report to the 20th National Con ress—Advancin the Health China Initiatives g g y

Population development strategy

3 Healthcare systems at once

China's children's drug market has tripled in 13 years since 2007
Actively develop medical insurance
Improve insurance and medical assistance system
Future focus on children's medicines (e.g. dosage forms, rare disease treatments, etc.)
Implement the settlement of medical treatment in different places and establish a long-term care insurance system

Preservation & innovation of traditional Chinese medicine

Proactive response to population aging

The proportion of chronic medical diseases in the country will increase to 68%
Establish a traditional Chinese medicine evaluation system suitable for its unique laws, and optimize traditional Chinese medicine with ancient classic prescriptions
Strengthen the comprehensive prevention and control of chronic diseases by promoting the use of medicines

© 2022 SCP, Ltd

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

17
----- End of picture text -----

Revenue Growth Strate - China gy

==> picture [72 x 71] intentionally omitted <==

Competitiveness

==> picture [67 x 54] intentionally omitted <==

Bio- Equivalence Execution

SCP has successful experience with U.S. and Japan regulatory dossiers
One completed
Expertise in Fasting & Fed BE design and execution

==> picture [71 x 73] intentionally omitted <==

==> picture [70 x 68] intentionally omitted <==

Medium-term targets

NMPA Consistency Evaluation

Self-developed products submission
6 ongoing cases, 4 of which were submitted for evaluation
Enhance profit sharing revenue

Cooperation

Strategy

Tech-transfer
Emphasize export and tech transfer simultaneously
Accelerate license acquisition, import MAH
License cooperation
Co-development
Profit-sharing Partnerships

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

Q

Self-owned medicine certificate and establishment of channel

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

18
----- End of picture text -----

Ja an Market Trend p

Sales quantity of generic drugs accounted for 71% of the total market, and sales amount accounted for 41% of the market.
The generic drug market is affected by rising prices and the depreciation of the yen. The cost accounts for 60 to 80% of the drug price. Total of 696 items (94 companies) in deficit according to MOHW’s survey. Scholars called on the Japanese government to implement short-term countermeasures

==> picture [666 x 254] intentionally omitted <==

----- Start of picture text -----

Sales Quantity Sales Amount
100% 100%
90% 90%
34% 31% 30% 29%
80% 41% 38% 80%
45%
70% 70% 59%
72% 70% 68% 65% 64% 63%
60% 60%
50% 50%
40% 40%
66% 69% 70% 71%
30% 59% 62% 30%
55%
20% 20% 28% 30% 32% 35% 36% 37% 41%
10% 10%
0% 0%
2015 2016 2017 2018 2019 2020 2021 2015 2016 2017 2018 2019 2020 2021
學名藥 Generic Drug 原廠藥 Brand Drug 學名藥 Generic Drug 原廠藥 Brand Drug
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

Q

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

19
----- End of picture text -----

Revenue Growth Strategy - Japan

==> picture [71 x 63] intentionally omitted <==

==> picture [67 x 64] intentionally omitted <==

Collaboration Model

Strategy

Agent for brand drugs.
CDMO
Collaboration with local company in different market.
Japan marketing partner
Strategic alliance with API manufacturer.
API Vertical Integration with Syn-Tech. On Going
License Holder

==> picture [69 x 65] intentionally omitted <==

----- Start of picture text -----

•
----- End of picture text -----

Current State

Ongoing export of Montelukast (Asthma) and Celecoxib (Antiinflammatory)
CDMO/CMO
Common items for China/ Southeast Asia/ Japan are under discussion
Obtained agency for gout new drug. Clinical trials in process, and it is expected to be launched in 2025

© 2022 SCP, Ltd

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

20
----- End of picture text -----

	US Market Trend	US Market Trend

	•	Executive order was signed on Sep.12, 2022 to invest more than $2 billion to
		support the domestic biotechnology industry.
	•	More than 80% of the APIs in the US are imported, and more than half of the APIs
		come from China and India.
	•	Ensuring the localized supply of APIs.
	•	Outsourced production needs have become an important	business source for
		Taiwan biotechnology industry.
		Item Content	Investment
		Strengthen Investment in APIs, antibiotics, and	$310 million in 5
		supplychains infectious disease drugs	years
		Expand US investment in biotechnology industry	$1.7 billion in 5
		production infrastructure Expend Investment in biofuels and chemicals	years $170 million	Q
		domestic market
		Innovation Provide innovation funds	over $200 million	21
©	2022 SCP, Ltd support

Revenue Growth Strate – U.S.A. gy

==> picture [154 x 110] intentionally omitted <==

U.S.A. Market

Largest Rx Market, with large proportion of generic drugs.
Drug certificate application is characterized by its complexity, lengthy review process, and its cost

==> picture [54 x 54] intentionally omitted <==

Current Status

Strategy

Co-develop new
Export of diabetic and amyotrophic lateral sclerosis(ALS) drugs.
products with pharmaceutical
- 2 drugs was P4 approved (drugs could be lunched during 2023 and 2024)
companies and dealers.
API Vertical Integration with Syn-Tech.

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

22
----- End of picture text -----

SCP’s Alliance with EASYWELL BIOMEDICALS

==> picture [426 x 278] intentionally omitted <==

EASYWELL’s US production base: Tulex Pharmaceuticals

Located in New Jersey
Obtained order from US department of Defense

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

Future Operation Strategy

Future From Taiwan to International From Generics to BTG

2023 2022 China USA、Japan

Core techniques and Increasing oversea professional Global marketing Marketing revenue 增加海核心技術 skills to expend & 專業海外市場操作 practices global sales turnover 借力使力  Enhance oversea sales’ 外比例 • Mature R&D techniques  Foundation improvement resources to create turnover  To speed up turnover  •  Hire international talents Plan and operate the Explore and learn different market with foreign market rules  companies Seeking medium to long-term partnership

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

24
----- End of picture text -----

==> picture [229 x 475] intentionally omitted <==

==> picture [88 x 81] intentionally omitted <==

Agenda

 Introduction of Standard Group  2022 Q1-Q3 Operating Results  Future Operation Strategy  Corporate Social Responsibility (CSR)

Fan Dao Nan Foundation

==> picture [156 x 115] intentionally omitted <==

Established in 1987
Endowment Fund: NT$196 Million
Annual Budget: NT$12 Million

==> picture [157 x 113] intentionally omitted <==

Principal Activities

Non-profit education

 Cultural and educational

 Children’s education and

development activities

Scholarships and Talent Cultivation happiness

==> picture [158 x 114] intentionally omitted <==

Rewards and Honors Received

 2011: Special Recognition Award – Ministry of Education

 2012: Tainan City Govt. Grant for Scholarship Program

 2013: National Special Selection Award for After-School Program – Dept. of Education

2022: Group Award on Social Education Contribution by Ministry Of Education

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

~~©~~

27
List of Group Award-MOE Social Education Contribution
Q
~~2022 SCP, Ltd~~
Y2021
Y2022
Taoyuan City LOHAS Pilot Education Society
ROC Foundation for Autistic Children and Adults in
Taiwan
Yuanta Cultural and Educational Foundation
Sin-Guang Visually Impaired Education Foundation
TSMC Education & Culture Foundation
ESUN Education & Culture Foundation
Maconix Education Foundation
Chun Yi Foundation
AAEON Foundation
First Commercial Bank Edu. & Cul. Foundation
ASUS Foundation
Doandelin Hope Foundation
Buddha’s Light International Association ROC
Feng-Nian Elementary School, Xinzhuang Dist., New
Taipei City
Juhu Elementary School
Mei Nong Ph.D. Scholar Association
Soil and Water Conservation Bureau Council of
Agriculture, Hualien Branch
Chang Gung Health and Culture Village
Water Source Education & Culture Foundation
Taiwan Reading Culture Foundation
Huiguang Yuanton Puxian Culture and Education
Foundation
Fan Dao Nan Foundation
Taisun Cultural Foundation
Chang Yung-Fa Foundation
Chen Qingbo Culture and Education Foundation
UMC Education & Culture Foundation
NOVATEK Education Foundation
National Library of Public Information
New Taipei City Banqiao Community University
Family Education Center of Tainan City

Corporate Social Responsibility: Jan~ Oct 2022

==> picture [88 x 81] intentionally omitted <==

Scholarships Hope After-school Class Sunflower Wednesdays
University (related fields): 4universities/5 students •Weekday afternoons •Every Wednesday afternoons
High school :5 schools, totaled 93 students Middle school:57schools, totaled 726 students •31 schools，2,545students •8 Schools，460 students  Elementary school :208schools,totaled 2,465 students
Total scholarship NTD 5.79 MM Total scholarship NTD 1.71MM Total scholarship NTD 400 KK Other Sponsorships Meal-Assistance Charity
Sponsorship to 12 non-for Provided 6,775 meals to  SCP Children’s Drawing
profit organization for students during winter and Competition
cultural and educational advancement summer vacation.  SCP National Table Tennis Q Competition*
Assisted Total- NTD 540KK
Grant Total- NTD 530 KK Suspended due to Covid-19 28

==> picture [16 x 15] intentionally omitted <==

Senior Gym in Taiwan – Athletic Training and Health Center

==> picture [153 x 211] intentionally omitted <==

==> picture [149 x 211] intentionally omitted <==

==> picture [315 x 179] intentionally omitted <==

Jan. to Oct. 2022,

The number of users is accumulated 54,998 user times.
16 health lectures were conducted regarding body healthcare and fitness

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [60 x 64] intentionally omitted <==

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

29
----- End of picture text -----

Communit Landsca in Ado tion y p g p

==> picture [336 x 236] intentionally omitted <==

==> picture [393 x 260] intentionally omitted <==

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [60 x 64] intentionally omitted <==

Cor orate Volunteer Fireman p

==> picture [567 x 381] intentionally omitted <==

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [60 x 64] intentionally omitted <==

==> picture [236 x 475] intentionally omitted <==

Q & A

==> picture [88 x 81] intentionally omitted <==

AI assistant

S.C.P.C — Interim / Quarterly Report 2022

51900_rns_2022-11-16_febda782-b271-408f-8740-262411242a31.pdf

免責聲明 Safe Harbor Notice

Agenda

Agenda

International Accreditation

Agenda

55 Years of Continuous Profitability

Comparison of Quarterly Revenue of Past 5 Years (Consolidated)

Consolidated Balance Sheet

Consolidated Cash Flows

Agenda

Future Milestone

SCP – Major International Businesses of the Past 2 Years

Revenue Growth Strate -Taiwan gy

China Market Trends: Current

China Market Trends: Report to the 20th National Con ress—Advancin the Health China Initiatives g g y

Population development strategy

3 Healthcare systems at once

© 2022 SCP, Ltd

Revenue Growth Strate - China gy

Competitiveness

Bio- Equivalence Execution

Medium-term targets

NMPA Consistency Evaluation

Cooperation

Strategy

Q

Ja an Market Trend p

Q

Revenue Growth Strategy - Japan

Collaboration Model

Strategy

Current State

© 2022 SCP, Ltd

Revenue Growth Strate – U.S.A. gy

U.S.A. Market

Current Status

Strategy

SCP’s Alliance with EASYWELL BIOMEDICALS

Future Operation Strategy

Agenda

Fan Dao Nan Foundation

Fan Dao Nan Foundation

Principal Activities

Rewards and Honors Received

Corporate Social Responsibility: Jan~ Oct 2022

Senior Gym in Taiwan – Athletic Training and Health Center

Jan. to Oct. 2022,

Communit Landsca in Ado tion y p g p

Cor orate Volunteer Fireman p

Q & A

More from S.C.P.C

S.C.P.C Interim / Quarterly Report 2022